Patent: 8,563,008
✉ Email this page to a colleague
Summary for Patent: 8,563,008
| Title: | Polynucleotides and polypeptides involved in gestational malaria, and biological applications |
| Abstract: | The disclosure provides novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including the sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to their for treating gestational malaria. Diagnostic methods and kits are described. |
| Inventor(s): | Deloron; Philippe Lucien (Paris, FR), Tuikue Ndam; Nicaise George (Paris, FR), Bertin; Gwladys Irenee (Neuilly Plaisance, FR), David; Peter (Paris, FR), Bischoff; Emmanuel (Boulogne-Billancourt, FR), Proux; Caroline Stephanie (Montigny le Bretonneux, FR), Coppee; Jean-Yves (Paris, FR), Salanti; Ali (Broenshoj, DK), Lavstsen; Thomas (Hoersholm, DK) |
| Assignee: | Institut de Recherche pour le Development (IRD) (Marseille Cedex, FR) Institut Pasteur (Paris, FR) |
| Application Number: | 12/450,874 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,563,008
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Par Pharmaceutical Companies, Inc. | APLISOL | tuberculin, purified protein derivative | Injection | 103782 | 04/20/1998 | ⤷ Try a Trial | 2027-04-17 |
| Sanofi Pasteur Limited | TUBERSOL | tuberculin, purified protein derivative | Injection | 103941 | 02/24/2000 | ⤷ Try a Trial | 2027-04-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
